RNS Number : 5837N
Genedrive PLC
30 September 2021

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, NEW ZEALAND OR THE REPUBLIC OF SOUTH AFRICA OR IN OR INTO ANY OTHER JURISDICTION WHERE TO DO SO WOULD BREACH ANY APPLICABLE LAW OR REGULATION.

THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT ITSELF CONSTITUTE AN OFFER FOR SALE OR SUBSCRIPTION OF ANY SECURITIES IN THE COMPANY OR CONTAIN ANY INVITATION, SOLICITATION, RECOMMENDATION, OFFER OR ADVICE TO ANY PERSON TO SUBSCRIBE FOR, OTHERWISE ACQUIRE OR DISPOSE OF ANY SECURITIES OF GENEDRIVE PLC IN ANY JURISDICTION.

genedrive plc

("genedrive", the "Group" or the "Company")

Result of General Meeting

London, UK - 30 September 2021: genedrive plc (LSE: GDR), the near patient molecular diagnostics company, announces that at the General Meeting held earlier today, the Resolutions proposed were duly passed by shareholders.

The full text of the resolutions can be found in the Notice of General Meeting set out in the shareholder circular published by the Company on 14 September 2021 which is available on the Company's website www.genedriveplc.com.

It is expected that Admission of the Placing Shares and the 4,450,852 Open Offer Shares for which valid acceptances were received will become effective at 8.00 a.m. on 1 October 2021. Following Admission, the Company will have 91,770,900 Ordinary Shares of 1.5p in issue each with equal voting rights. No shares are held in treasury.

The above figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interest, or a change to their interest, in the Company under the FCA's Disclosure Guidance and Transparency Rules.

Unless otherwise defined, terms in this announcement shall have the same meanings as those defined in the Proposed Placing and Open Offer announcement issued on 10 September 2021.

For further information, please contact:

genedrive plc David Budd (Chief Executive Officer) Matthew Fowler (Chief Financial Officer)	+44 (0) 161 989 0245
Peel Hunt LLP - **Nominated Adviser, Joint Broker and Bookrunner** James Steel (Investment Banking) Jock Maxwell Macdonald / Sohail Akbar (ECM)	+44 (0) 20 7148 8900
finnCap Ltd - Joint Broker and Bookrunner Geoff Nash / Kate Bannatyne (Corporate Finance) Alice Lane / Harriet Ward (ECM)	+44 (0) 20 7220 0500
Walbrook PR - Financial PR & IR Adviser Paul McManus / Anna Dunphy	+44 (0) 20 7933 8780

About genedrive plc (http://www.genedriveplc.com) genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Company has assays on market for the detection of HCV and certain military biological targets. The Company released a high throughput SARS-CoV-2 assay in 2020, and has a point of care version of the SARS-Cov-2 test in development. Antibiotic Induced Hearing Loss represents the Company's first targeting of the Genedrive® system into an emergency/urgent care environment.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

ROMWPUGABUPGGGU